Published online before print April 11, 2002, doi: 10.1161/01.ATV.0000018304.30943.06
© 2002 American Heart Association, Inc.
Atherosclerosis and Lipoproteins |
Normal Production Rate of Apolipoprotein B in LDL Receptor–Deficient Mice
From the Department of Medicine, University of Pennsylvania, Philadelphia.
Correspondence to John S. Millar, PhD, University of Pennsylvania, Department of Medicine, 644 BRB II/III, 421 Curie Blvd, Philadelphia, PA 19104. E-mail jsmillar{at}mail.med.upenn.edu
Abstract— The low density lipoprotein (LDL) receptor is well known for its role in mediating the removal of apolipoprotein B (apoB)-containing lipoproteins from plasma. Results from in vitro studies in primary mouse hepatocytes suggest that the LDL receptor may also have a role in the regulation of very low density lipoprotein (VLDL) production. We conducted in vivo experiments using LDLR-/-, LDLR+/-, and wild-type mice (LDLR indicates LDL receptor gene) in which the production rate of VLDL was measured after the injection of [35S]methionine and the lipase inhibitor Triton WR1339. Despite the fact that LDLR-/- mice had a 3.7-fold higher total cholesterol level and a 2.1-fold higher triglyceride level than those of the wild-type mice, there was no difference in the production rate of VLDL triglyceride or VLDL apoB between these groups of animals. Experiments were also conducted in apobec1-/- mice, which make only apoB-100, the form of apoB that binds to the LDL receptor. Interestingly, the apobec1-/- mice had a significantly higher production rate of apoB than did the wild-type mice. However, despite significant differences in total cholesterol and triglyceride levels, there was no difference in the production rate of total or VLDL triglyceride or VLDL apoB between LDLR-/- and LDLR+/- mice on an apobec1-/- background. These results indicate that the LDL receptor has no effect on the production rate of VLDL triglyceride or apoB in vivo in mice.
Key Words: triglycerides • very low density lipoproteins • familial hypercholesterolemia • Triton WR1339 • apobec1
This article has been cited by other articles:
 |
|
 |
|
  M. A. Pellizzon, J. T. Billheimer, L. T. Bloedon, P. O. Szapary, and D. J. Rader Flaxseed Reduces Plasma Cholesterol Levels in Hypercholesterolemic Mouse Models J. Am. Coll. Nutr., February 1, 2007; 26(1): 66 - 75. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. S. Millar, S. J. Stone, U. J. F. Tietge, B. Tow, J. T. Billheimer, J. S. Wong, R. L. Hamilton, R. V. Farese Jr., and D. J. Rader Short-term overexpression of DGAT1 or DGAT2 increases hepatic triglyceride but not VLDL triglyceride or apoB production J. Lipid Res., October 1, 2006; 47(10): 2297 - 2305. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. S. Millar, D. A. Cromley, M. G. McCoy, D. J. Rader, and J. T. Billheimer Determining hepatic triglyceride production in mice: comparison of poloxamer 407 with Triton WR-1339 J. Lipid Res., September 1, 2005; 46(9): 2023 - 2028. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Lalanne, G. Lambert, M. J. A. Amar, M. Chetiveaux, Y. Zair, A.-L. Jarnoux, K. Ouguerram, J. Friburg, N. G. Seidah, H. B. Brewer Jr., et al. Wild-type PCSK9 inhibits LDL clearance but does not affect apoB-containing lipoprotein production in mouse and cultured cells J. Lipid Res., June 1, 2005; 46(6): 1312 - 1319. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. S. Millar, C. Maugeais, K. Ikewaki, D. M. Kolansky, P.H. R. Barrett, E. C. Budreck, R. C. Boston, N. Tada, S. Mochizuki, J. C. Defesche, et al. Complete Deficiency of the Low-Density Lipoprotein Receptor Is Associated With Increased Apolipoprotein B-100 Production Arterioscler. Thromb. Vasc. Biol., March 1, 2005; 25(3): 560 - 565. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Nassir, Y. Xie, B. W. Patterson, J. Luo, and N. O. Davidson Hepatic secretion of small lipoprotein particles in apobec-1-/- mice is regulated by the LDL receptor J. Lipid Res., September 1, 2004; 45(9): 1649 - 1659. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. D. Attie The Mystery of PCSK9 Arterioscler. Thromb. Vasc. Biol., August 1, 2004; 24(8): 1337 - 1339. [Full Text] [PDF]
|
|
|
|
 |
|
 D. V. Chirieac, H. L. Collins, J. Cianci, J. D. Sparks, and C. E. Sparks Altered triglyceride-rich lipoprotein production in Zucker diabetic fatty rats Am J Physiol Endocrinol Metab, July 1, 2004; 287(1): E42 - E49. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Sahoo, T. C. Trischuk, T. Chan, V. A. B. Drover, S. Ho, G. Chimini, L. B. Agellon, R. Agnihotri, G. A. Francis, and R. Lehner ABCA1-dependent lipid efflux to apolipoprotein A-I mediates HDL particle formation and decreases VLDL secretion from murine hepatocytes J. Lipid Res., June 1, 2004; 45(6): 1122 - 1131. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. J. Tremblay, B. Lamarche, I. L. Ruel, J.-C. Hogue, J. Bergeron, C. Gagne, and P. Couture Increased production of VLDL apoB-100 in subjects with familial hypercholesterolemia carrying the same null LDL receptor gene mutation J. Lipid Res., May 1, 2004; 45(5): 866 - 872. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. L. Larsson, J. Skogsberg, and J. Bjorkegren The Low Density Lipoprotein Receptor Prevents Secretion of Dense ApoB100-containing Lipoproteins from the Liver J. Biol. Chem., January 9, 2004; 279(2): 831 - 836. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. M. Borradaile, L. E. de Dreu, and M. W. Huff Inhibition of Net HepG2 Cell Apolipoprotein B Secretion by the Citrus Flavonoid Naringenin Involves Activation of Phosphatidylinositol 3-Kinase, Independent of Insulin Receptor Substrate-1 Phosphorylation Diabetes, October 1, 2003; 52(10): 2554 - 2561. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. M. Turner, E. J. Murphy, R. A. Neese, F. Antelo, T. Thomas, A. Agarwal, C. Go, and M. K. Hellerstein Measurement of TG synthesis and turnover in vivo by 2H2O incorporation into the glycerol moiety and application of MIDA Am J Physiol Endocrinol Metab, October 1, 2003; 285(4): E790 - E803. [Abstract] [Full Text] [PDF]
|
|